OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.06.

OncoCyte Stock Up 11.3 %

Shares of NASDAQ OCX opened at $3.34 on Friday. OncoCyte has a one year low of $2.08 and a one year high of $4.34. The business’s fifty day moving average price is $3.13 and its 200-day moving average price is $2.94.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The business had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.